Description
Introduction
Levetiracetam is an antiepileptic , which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
Levetiracetam has been approved in the United States as add-on treatment for partial (focal), myoclonic, and tonic-clonic seizures. Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures, or as an adjunctive therapy for partial, myoclonic, and tonic-clonic seizures.Levetiracetam has been shown to reduce partial (focal) seizures by 50% or more as an add-on medication.It is also used in veterinary medicine for similar purposes. Based on low-quality evidence, levetiracetam is about as effective as phenytoin for prevention of early seizures after traumatic brain injury.
Levetiracetam is an antiepileptic ,, which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
1) Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures
2) Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome
Levetiracetam is an antiepileptic , which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
Levetiracetam has been approved in the United States as add-on treatment for partial (focal), myoclonic, and tonic-clonic seizures. Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures, or as an adjunctive therapy for partial, myoclonic, and tonic-clonic seizures.Levetiracetam has been shown to reduce partial (focal) seizures by 50% or more as an add-on medication.It is also used in veterinary medicine for similar purposes. Based on low-quality evidence, levetiracetam is about as effective as phenytoin for prevention of early seizures after traumatic brain injury.
Levetiracetam is an antiepileptic ,, which is mainly used for the combined treatment of partial seizures in adults and children over 4 years old.
1) Levetiracetam has been approved in the European Union as a monotherapy treatment for epilepsy in the case of partial seizures
2) Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome
3) It is also sometimes used to treat neuropathic pain
| Name of product | LEVETIRACETAM |
| Characters | White Or White crystals Powder |
| Identification | |
| A:Specific optical rotation | -76°to -82° |
| B:IR | The spectrum obtained from samples consists with that obtained from reference substance |
| C:Enantiomeric purity | Meet the requirement (see tests) |
| TESTS | |
| Appearance of solution | Clear and not more intensely coloured than BY6 |
| Enantiomeric purity (impurity D ) | Not more than 0.8% |
| Related substances | |
| Impurity A | Not more than 0.3% |
| Unspecified impurity | Not more than 0.05% |
| Sunof unspecified impurities | Not more than 0.1% |
| Total impurities | Not more than 0.4% |
| Impurity F | Not more than 0.1% |
| Heavy metals | Not more than 10ppm |
| Water | Not more than 0.5% |
| Sulfated Ash | Not more than 0.1% |
| Residual solvents | |
| Acetone | Not more than 5000ppm |
| Assay Dichloromethane | Not more than 600ppm |
| Ethyl acetate | Not more than 5000ppm |
| Benzene | Not more than 2ppm |
| Assay (on anhydrous basis ) | 98.0%-102.0% OF C8H4N2O2 |
